BIONEXUS GENE LAB CORP (BGLC:NASDAQ)

$2.22 0.15 (7.2464%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 65

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed BIONEXUS GENE LAB CORP (BGLC:NASDAQ) News Sources

BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology

30-07-2025

yahoo.com

Top Midday Gainers

30-07-2025

yahoo.com

BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities

10-11-2025

yahoo.com

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization

12-11-2025

yahoo.com

BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene

01-12-2025

yahoo.com

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization

02-12-2025

yahoo.com

BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™

03-12-2025

yahoo.com

BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market

28-01-2026

yahoo.com

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

23-02-2026

yahoo.com

BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform

11-03-2026

yahoo.com

BIONEXUS GENE LAB CORP (BGLC:NASDAQ) Sentiment Trend

0 25 50 75 100 72 63 63 65 65 71 65 60 54 69 30-07-2025 10-11-2025 12-11-2025 01-12-2025 02-12-2025 03-12-2025 28-01-2026 23-02-2026 11-03-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

BIONEXUS GENE LAB CORP (BGLC:NASDAQ) FAQs

toggle

What is the current price of BIONEXUS GENE LAB CORP (BGLC:NASDAQ)?

The current price of BIONEXUS GENE LAB CORP (BGLC:NASDAQ) is $2.22.


toggle

BIONEXUS GENE LAB CORP (BGLC:NASDAQ) absolute price change since previous trading day?

The absolute price change of BIONEXUS GENE LAB CORP (BGLC:NASDAQ) since the previous trading day is $0.15.


toggle

BIONEXUS GENE LAB CORP (BGLC:NASDAQ) percentage price change since previous trading day?

The percentage price change of BIONEXUS GENE LAB CORP (BGLC:NASDAQ) since the previous trading day is 7.2464%.


toggle

What is the most recent average sentiment score for BIONEXUS GENE LAB CORP (BGLC:NASDAQ)?

The most recent average sentiment score for BIONEXUS GENE LAB CORP (BGLC:NASDAQ) is 65 out of 100.


toggle

What is the most recent average sentiment for BIONEXUS GENE LAB CORP (BGLC:NASDAQ)?

The most recent sentiment for BIONEXUS GENE LAB CORP (BGLC:NASDAQ) is .


SEC-8K** Filing Available For BIONEXUS GENE LAB CORP (BGLC:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.